Gali Prag
Co-Founder & Board Member Coltac Therapeutics
Gali Prag is Professor at Tel Aviv University and Co-Founder of COLTAC Therapeutics, where his research focuses on ubiquitin biology, protein-protein interactions, and cellular signaling. His work has advanced understanding of ubiquitin-mediated regulation and led to the development of innovative molecular glue discovery platforms targeting previously undruggable proteins.
Seminars
Thursday 28th January 2027
Expanding Molecular Glue Discovery Beyond Degradation: Identifying Transcription Factor Inhibitors Through Conformational Trapping
12:00 pm
- Overcoming the challenge of drugging transcription factors by developing a functional E. coli screening platform to identify molecular glues that trap proteins in inactive conformations
- Moving beyond degradation by selectively preventing transcription factor DNA binding and suppressing downstream gene expression through induced conformational control
- Combining computational screening and functional validation to rapidly discover potent molecular glue candidates and accelerate translation into cellular and in vivo models
